NVAX — Novavax Inc
NASDAQ · Healthcare · Biotechnology
$10.26
+$0.14 (+1.33%)
Novavax Inc (NVAX) is a biotechnology company listed on NASDAQ. It is led by John Charles Jacobs M.B.A., based in 700 Quince Orchard Road, Gaithersburg, MD, United States, 20878, with about 952 employees. Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Latest reported NVAX revenue for 2025-09-30 was $70.4M. Net income was -$202.4M. Revenue was down 70.6% from 2025-06-30 to 2025-09-30. NVAX currently screens at market cap $1.09B and trailing P/E 2.5.
Use this NVAX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the NVAX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the NVAX SEC filings page. Lician reads the product cache first so this HTML stays unique to Novavax Inc even when a live quote feed is slow.
About Novavax Inc
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
NVAX Key Statistics
Market Cap
$1.09B
Volume
921,472
Previous Close
$8.07
Day Range
$7.83 – $8.08
P/E Ratio
2.46
EPS
-$1.23
Revenue
$682.16M
Net Income
-$187.50M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-30.7%
Profit Margin
-27.5%
Employees
952
NVAX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $682.16M | $983.71M | $1.98B | $1.15B |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$187.50M | -$545.06M | -$657.94M | -$1.74B |
| EPS (Diluted) | -$1.23 | -$5.41 | -$8.42 | -$23.44 |
Total Assets
$1.56B
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$530.23M
Operating Cash Flow
-$87.26M
Free Cash Flow
$0.00
Novavax Inc Company Information
- President, CEO & Director
- John Charles Jacobs M.B.A.
- Headquarters
- 700 Quince Orchard Road, Gaithersburg, MD, United States, 20878
- Website
- www.novavax.com
- Phone
- 240 268 2000
- IPO / Founded
- 1995-12-05
- Sector
- Healthcare
- Industry
- Biotechnology